2nd Annual NASH Summit Europe

Memo

Built from research with the FDA, EMA and Gilead, the 2nd Annual NASH Summit Europe will once again elevate industry-to-industry dialogue and reveal leading insights in overcoming the hurdles limiting NASH therapeutic success. Join the NASH community as they collectively address the biggest challenges in NASH through a tighter lens including the potential for stand-alone versus combination therapeutics, the genetic drivers influencing disease heterogeneity and the future payer and reimbursement landscape. Hear from 22 stakeholders including Pfizer, Novartis and MedImmune as this exclusively drug development driven forum equips you with the connections and actionable takeaways you need to capture one of many market opportunities for a successful NASH candidate.